Ian Thompson, MD
Ophthalmology · Albuquerque, NMNPI 1154769958
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,045 of the $9,742 with a category attached, or 82.6%. Genentech USA, Inc. accounts for 93.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $8,960 and has fallen 97.5% since, to $228 in 2025. Among ophthalmology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $347.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$9K
- Alcon$223
- AbbVie$162
- Regeneron Healthcare Solutions, Inc.$128
- Biogen$41
- Apellis Pharmaceuticals, Inc.$32
- plus $24 from 1 others
What the payments were for
- Consulting fees$8,04583%
- Travel & lodging$5315%
- Food & beverage$1,16712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 13 | $9,131 |
| Alcon | 2 | $223 |
| AbbVie(2 entities) | 5 | $162 |
| Regeneron Healthcare Solutions, Inc. | 4 | $128 |
| Biogen | 2 | $41 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,742 in reported general payments places this provider in the 90th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 190 | $5,987 |
| Difluprednate | 45 | $3,877 |
| Brimonidine Tartrate | 41 | $2,787 |
| Ofloxacin | 97 | $1,231 |
| Latanoprost | 54 | $873 |
| Atropine Sulfate | 15 | $713 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $637 |
| Dorzolamide Hcl | 19 | $382 |
| ErythromycinErythromycin Base | 18 | $256 |
| Prednisone | 22 | $226 |
| Timolol Maleate | 26 | $158 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Albuquerque
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
- Iuri GolubevAlbuquerque$7K
- Thomas GilletteAlbuquerque$6K
- Kenneth DownesAlbuquerque$5K
- Arup DasAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.